Key Insights

Highlights

Success Rate

70% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

11.5%

3 terminated out of 26 trials

Success Rate

70.0%

-16.5% vs benchmark

Late-Stage Pipeline

12%

3 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed with results

Key Signals

2 with results70% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (11)
Early P 1 (1)
P 1 (3)
P 2 (3)
P 3 (3)

Trial Status

Unknown7
Completed7
Recruiting5
Terminated3
Not Yet Recruiting2
Active Not Recruiting1

Trial Success Rate

70.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT04081246Not ApplicableCompleted

Transurethral Modified En Bloc Resection For Large Bladder Tumours.

NCT06940648Not ApplicableEnrolling By InvitationPrimary

Virtuoso Improving Anatomic Bladder Lesion Excision (VIABLE) Trial

NCT07664397Phase 1Not Yet Recruiting

Imaging Study of [89Zr]DFO-YS5 for Cancer Detection

NCT04075305Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

NCT07234968Not ApplicableRecruiting

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

NCT07067749Phase 3Recruiting

Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer

NCT04167631Not ApplicableActive Not Recruiting

Can VI-RADS/ADC Accurately Stage Bladder Cancer??

NCT06528483Phase 2Not Yet Recruiting

Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer

NCT06416319Not ApplicableRecruiting

Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct)

NCT04200963Phase 1Completed

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

NCT06167356Recruiting

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

NCT05540847Not ApplicableCompletedPrimary

Comparison of Interfascial Injection Versus Subpectineal Injection on Ultrasound-guided Obturator Nerve Block

NCT03458598Not ApplicableCompletedPrimary

Pre-Operative Single Shot Rectus Sheath Block

NCT05467267UnknownPrimary

Personalized Urine Biomarker for Patients With Bladder Cancer

NCT04839029Not ApplicableUnknown

Bipolar Versus Mono-polar Needlescopic En Bloc TUR-BT

NCT04784507Phase 2UnknownPrimary

En-Bloc Resection of Bladder Tumors

NCT05134623UnknownPrimary

Smurf2 Gene Expression in Urinary Tract Tumors

NCT05027412Not ApplicableUnknown

En Bloc TURBT With Collins Loop vs Conventional TURBT

NCT05022160Early Phase 1UnknownPrimary

Preventing Catheter Related Bladder Discomfort (CRBD) With Bilateral Pudendal Nerve Block

NCT03335059Phase 3Terminated

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.

Scroll to load more

Research Network

Activity Timeline